DK2866797T3 - Stabil injicerbar farmaceutisk sammensætning med neurokinin 1- receptorantagonist og fremgangsmåde til fremstilling deraf - Google Patents
Stabil injicerbar farmaceutisk sammensætning med neurokinin 1- receptorantagonist og fremgangsmåde til fremstilling deraf Download PDFInfo
- Publication number
- DK2866797T3 DK2866797T3 DK12756353.4T DK12756353T DK2866797T3 DK 2866797 T3 DK2866797 T3 DK 2866797T3 DK 12756353 T DK12756353 T DK 12756353T DK 2866797 T3 DK2866797 T3 DK 2866797T3
- Authority
- DK
- Denmark
- Prior art keywords
- injective
- neurokinin
- stable
- preparation
- pharmaceutical composition
- Prior art date
Links
- 229940123821 Neurokinin 1 receptor antagonist Drugs 0.000 title 1
- PFPSZGPAQFBVHZ-UHFFFAOYSA-N n-(3-chlorophenyl)-2-[(4-phenyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)sulfanyl]acetamide Chemical compound ClC1=CC=CC(NC(=O)CSC=2N(C(C=3C=CN=CC=3)=NN=2)C=2C=CC=CC=2)=C1 PFPSZGPAQFBVHZ-UHFFFAOYSA-N 0.000 title 1
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fencing (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/002854 WO2014005606A1 (en) | 2012-07-06 | 2012-07-06 | Stable injectable pharmaceutical composition of neurokinin 1 receptor antagonist and process for preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2866797T3 true DK2866797T3 (da) | 2020-08-03 |
Family
ID=46826407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12756353.4T DK2866797T3 (da) | 2012-07-06 | 2012-07-06 | Stabil injicerbar farmaceutisk sammensætning med neurokinin 1- receptorantagonist og fremgangsmåde til fremstilling deraf |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20150165045A1 (da) |
| EP (1) | EP2866797B1 (da) |
| CY (1) | CY1123370T1 (da) |
| DK (1) | DK2866797T3 (da) |
| ES (1) | ES2798103T3 (da) |
| HR (1) | HRP20201138T1 (da) |
| HU (1) | HUE051147T2 (da) |
| LT (1) | LT2866797T (da) |
| PL (1) | PL2866797T3 (da) |
| PT (1) | PT2866797T (da) |
| RS (1) | RS60599B1 (da) |
| SI (1) | SI2866797T1 (da) |
| SM (1) | SMT202000385T1 (da) |
| WO (1) | WO2014005606A1 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015054429A1 (en) | 2013-10-08 | 2015-04-16 | Innopharma, Inc | Aprepitant oral liquid formulations |
| WO2015101596A2 (en) * | 2013-12-30 | 2015-07-09 | Oncoprevent Gmbh | Neurokinin-1 receptor antagonists for use in a method of prevention of cancer |
| EP3171894B1 (en) * | 2014-07-24 | 2021-03-24 | Plus Vitech, S.L. | Neurokinin-1 receptor antagonist composition for treatment of diseases and conditions of the respiratory tract |
| WO2016044784A1 (en) | 2014-09-19 | 2016-03-24 | Heron Therapeutics, Inc. | Emulson formulations of aprepitant |
| WO2017021880A1 (en) * | 2015-08-03 | 2017-02-09 | Leiutis Pharmaceuticals Pvt Ltd | Liquid formulations of fosaprepitant |
| US9913853B2 (en) | 2015-11-03 | 2018-03-13 | Cipla Limited | Stabilized liquid fosaprepitant formulations |
| KR20180118136A (ko) * | 2016-02-01 | 2018-10-30 | 헤론 테라퓨틱스 인코포레이티드 | Nk-1 수용체 길항제를 포함하는 에멀젼 |
| US9974742B2 (en) | 2016-02-01 | 2018-05-22 | Heron Therapeutics, Inc. | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
| PT3435980T (pt) * | 2016-06-06 | 2020-02-21 | Helsinn Healthcare Sa | Formulações injetáveis fisiologicamente equilibradas de fosnetupitant |
| US20190175702A1 (en) * | 2016-08-03 | 2019-06-13 | Zhuhai Beihai Biotech Co., Ltd. | Formulations of fosaprepitant and aprepitant |
| JP2021512091A (ja) * | 2018-01-30 | 2021-05-13 | ヘロン セラピューティクス, インコーポレイテッドHeron Therapeutics, Inc. | Nk−1受容体アンタゴニストのエマルジョン製剤の投与方法 |
| US11654154B2 (en) | 2019-01-29 | 2023-05-23 | Navinta Iii Inc | Process for preparing injectable Fosaprepitant Dimeglumine compositions having improved storage stability |
| CN112168788B (zh) * | 2019-07-01 | 2022-07-19 | 中国医学科学院药物研究所 | 静脉注射用阿瑞匹坦胶束无菌冻干制剂及其制备方法 |
| CN110559255B (zh) * | 2019-09-06 | 2022-08-19 | 南京医科大学 | Zl006温敏凝胶及其制备方法 |
| WO2023197637A1 (en) * | 2022-04-14 | 2023-10-19 | Wisdom Pharmaceutical Co., Ltd. | Pharmaceutical composition, and aprepitant injection and freeze-dried powder injection |
| CN115944745B (zh) * | 2022-12-01 | 2024-03-22 | 石河子大学 | 一种具有聚集诱导发光性质的活性氧响应型药物控释体系及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1082959A1 (en) | 1991-09-20 | 2001-03-14 | Glaxo Group Limited | NK1 Antagonists for the treatment of depression |
| IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| JP2008517927A (ja) * | 2004-10-21 | 2008-05-29 | ユニバーシティー オブ アイオワ リサーチ ファンデーション | insitu制御放出薬剤送達システム |
| US9227958B2 (en) * | 2006-02-03 | 2016-01-05 | Glenmark Pharmaceuticals Limited | Amorphous and crystalline forms of aprepitant and processes for the preparation thereof |
| WO2007128056A1 (en) * | 2006-05-03 | 2007-11-15 | Cnsbio Pty Ltd | Methods and composition for treatment of inflammatory pain |
| US20070265329A1 (en) | 2006-05-12 | 2007-11-15 | Devang Shah T | Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) |
| WO2008110534A1 (en) * | 2007-03-13 | 2008-09-18 | Sandoz Ag | Pharmaceutical compositions of poorly soluble drugs |
| ES2620672T3 (es) * | 2008-01-09 | 2017-06-29 | Charleston Laboratories, Inc. | Comprimidos de doble capa que comprenden oxicodona y prometazina |
| EP2310019A4 (en) * | 2008-05-29 | 2011-06-01 | Albany Molecular Res Inc | 5-HT3 RECEPTOR MODULATORS, MANUFACTURING METHOD AND ITS USE |
| WO2011006012A1 (en) * | 2009-07-08 | 2011-01-13 | Charleston Laboratories Inc. | Pharmaceutical compositions |
| HUP1000325A2 (en) * | 2010-06-18 | 2012-01-30 | Druggability Technologies Ip Holdco Jersey Ltd | Nanostructured aprepitant compositions and process for their preparation |
-
2012
- 2012-07-06 DK DK12756353.4T patent/DK2866797T3/da active
- 2012-07-06 SI SI201231807T patent/SI2866797T1/sl unknown
- 2012-07-06 WO PCT/EP2012/002854 patent/WO2014005606A1/en not_active Ceased
- 2012-07-06 SM SM20200385T patent/SMT202000385T1/it unknown
- 2012-07-06 EP EP12756353.4A patent/EP2866797B1/en active Active
- 2012-07-06 HU HUE12756353A patent/HUE051147T2/hu unknown
- 2012-07-06 PT PT127563534T patent/PT2866797T/pt unknown
- 2012-07-06 HR HRP20201138TT patent/HRP20201138T1/hr unknown
- 2012-07-06 US US14/412,147 patent/US20150165045A1/en not_active Abandoned
- 2012-07-06 RS RS20200846A patent/RS60599B1/sr unknown
- 2012-07-06 ES ES12756353T patent/ES2798103T3/es active Active
- 2012-07-06 LT LTEP12756353.4T patent/LT2866797T/lt unknown
- 2012-07-06 PL PL12756353T patent/PL2866797T3/pl unknown
-
2020
- 2020-04-17 US US16/851,779 patent/US20200237920A1/en not_active Abandoned
- 2020-07-07 CY CY20201100624T patent/CY1123370T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20201138T1 (hr) | 2020-10-30 |
| WO2014005606A1 (en) | 2014-01-09 |
| EP2866797B1 (en) | 2020-04-29 |
| CY1123370T1 (el) | 2021-12-31 |
| RS60599B1 (sr) | 2020-08-31 |
| PT2866797T (pt) | 2020-07-22 |
| SI2866797T1 (sl) | 2020-08-31 |
| US20150165045A1 (en) | 2015-06-18 |
| PL2866797T3 (pl) | 2020-11-02 |
| LT2866797T (lt) | 2020-06-25 |
| HUE051147T2 (hu) | 2021-03-01 |
| ES2798103T3 (es) | 2020-12-09 |
| US20200237920A1 (en) | 2020-07-30 |
| SMT202000385T1 (it) | 2020-11-10 |
| EP2866797A1 (en) | 2015-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2866797T3 (da) | Stabil injicerbar farmaceutisk sammensætning med neurokinin 1- receptorantagonist og fremgangsmåde til fremstilling deraf | |
| IL274798A (en) | Ph20 polypeptide variants, formulations and uses thereof | |
| HUE051400T2 (hu) | Lipofil gyógyászati szerek javított parenterális kiszerelései és eljárások azok elõállítására és alkalmazására | |
| DK3284467T3 (da) | Nikotinholdige farmaceutiske sammensætninger | |
| DK2877599T3 (da) | Fremgangsmåder og sammensætninger til bestemmelse af resistens overfor androgenreceptorterapi | |
| HUE053360T2 (hu) | Kompozíciók és eljárások mutációk pontos azonosítására | |
| PL2922526T3 (pl) | Wytwarzanie półplastycznych farmaceutycznych jednostek dawkowania | |
| ME03465B (me) | Farmaceutska kompozicija s-ketamin hidrohlorida | |
| LT3222272T (lt) | Farmacinė karbetocino kompozicija | |
| BR112014010290A2 (pt) | composição farmacêutica, métodos, composições e usos | |
| IL234884A0 (en) | Inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use | |
| IT1398930B1 (it) | Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi. | |
| HUE037664T2 (hu) | Állati takarmány és eljárás annak elõállítására | |
| DK2917358T3 (da) | Sammensætninger og fremgangsmåder til biologisk fremstilling af fedtsyrederivater | |
| IL229963A0 (en) | Substituted quinolines and their use as medicaments | |
| HRP20180915T1 (hr) | Spojevi koji imaju aktivnost kao antagonist muskarinskog receptora i kao agonist beta2 adrenergijskog receptora | |
| HUE056943T2 (hu) | CCR3 antagonistákat tartalmazó gyógyászati készítmények | |
| DK2815752T3 (da) | Oral farmaceutisk sammensætning | |
| EP2925340A4 (en) | Pharmaceutical compositions and therapeutic methods of use comprising selective agonists of melanocortin 1 receptor | |
| BR112013033472A2 (pt) | derivado de camptotecina e método de preparação do mesmo e composição farmacêutica e aplicação | |
| FI20125888A7 (fi) | Anisomelihapon farmaseuttiset koostumukset ja niiden käyttö | |
| SMT201500005B (it) | Composizione framaceutica inalabile | |
| DK2525827T3 (da) | Farmaceutiske formuleringer af loratadin til indkapsling og kombinationer deraf | |
| PL2956011T3 (pl) | Kompozycja do żucia do podawania doustnego i sposób jej wytwarzania | |
| DK3517532T3 (da) | Fremgangsmåde til fremstilling af anamorelinhydrochlorid med reguleret chloridindhold |